|
rs4986791
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Our result indicated that two Single Nucleotide Polymorphisms (SNP) in TLR4 were associated with decreased cancer risk for rs4986791</span>: OR = 0.764, 95% CI: 0.652-0.894, <i>P =</i> 0.001 in allele model; OR = 0.769, 95%CI: 0.650-0.909, <i>P =</i> 0.002 in recessive model; OR = 0.505, 95% CI: 0.352-0.726, <i>P =</i> 0.000 in dominant model; for 11536889: OR = 0.927, 95% CI: 0.872-0.984, <i>P =</i> 0.013 in allele model; OR = 0.926, 95% CI: 0.862-0.944,<i>P =</i> 0.034 in recessive model.
|
29246004 |
2017 |
|
rs4986790
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Many epidemiological studies have shown the association between certain genetic variations in the Toll-like receptor 4 (TLR4) gene (for example, rs4986790 and rs4986791) and cancer risk.
|
26782430 |
2015 |
|
rs4986791
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Many epidemiological studies have shown the association between certain genetic variations in the Toll-like receptor 4 (TLR4) gene (for example, rs4986790 and rs4986791) and cancer risk.
|
26782430 |
2015 |
|
rs4986790
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The results showed that all of these three polymorphisms were significantly associated with the increased cancer risk (dominant model: OR = 1.64, 95% CI: 1.04-2.60 for TLR2 -196 to -174 del; OR = 1.19, 95% CI: 1.01-1.41 for TLR4 rs4986790; and OR = 1.47, 95% CI: 1.120-1.80 for TLR4 rs4986791; respectively).
|
24376595 |
2013 |
|
rs4986790
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Our meta-analysis identified that two SNPs (rs4986790 and rs4986791) in TLR4 were associated with increased cancer risk (for rs4986790: OR=1.24, 95% CI=1.01-1.52 in dominant model; OR=1.24, 95% CI=1.02-1.52 in overdominant model; for rs4986791: OR=1.81, 95% CI=1.18-2.77 in allele comparison; OR=1.79, 95% CI=1.15-2.80 in dominant model; OR=1.70, 95% CI=1.09-2.67 in overdominant model) and one SNP (rs1927911) in TLR4 was associated with decreased cancer risk (for rs1927911: OR=0.63, 95% CI=0.41-0.99 in allele comparison; OR=0.57, 95% CI=0.35-0.95 in dominant model; OR=0.67, 95% CI=0.46-0.97 in codominant model).
|
23084080 |
2013 |
|
rs4986791
|
|
|
0.060 |
GeneticVariation |
BEFREE |
However, the association between rs4986791 and cancer risk was significant in both South Asians and East Asians, but not in Caucasians.
|
24376595 |
2013 |
|
rs4986791
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Our meta-analysis identified that two SNPs (rs4986790 and rs4986791) in TLR4 were associated with increased cancer risk (for rs4986790: OR=1.24, 95% CI=1.01-1.52 in dominant model; OR=1.24, 95% CI=1.02-1.52 in overdominant model; for rs4986791: OR=1.81, 95% CI=1.18-2.77 in allele comparison; OR=1.79, 95% CI=1.15-2.80 in dominant model; OR=1.70, 95% CI=1.09-2.67 in overdominant model) and one SNP (rs1927911) in TLR4 was associated with decreased cancer risk (for rs1927911: OR=0.63, 95% CI=0.41-0.99 in allele comparison; OR=0.57, 95% CI=0.35-0.95 in dominant model; OR=0.67, 95% CI=0.46-0.97 in codominant model).
|
23084080 |
2013 |
|
rs4986790
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Recently, a number of case-control studies were conducted to investigate the association between TLR4 gene polymorphism and cancer risk, especially Asp299Gly and Thr399Ile polymorphisms.
|
22441122 |
2012 |
|
rs4986791
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Thr399Ile polymorphism was significantly associated with an elevated cancer risk in overall analysis (T allele versus C allele, OR=1.72, 95% CI: 1.27-2.33; TC versus CC, OR=1.63, 95% CI: 1.18-2.26; TT+TC versus CC, OR=1.70, 95% CI: 1.24-2.34) and especially in gastrointestinal subgroup (T allele versus C allele, OR=2.01, 95% CI: 1.40-2.89; TC versus CC, OR=1.86, 95% CI: 1.26-2.74; TT+TC versus CC, OR=1.97, 95% CI: 1.35-2.88).
|
22441122 |
2012 |
|
rs4986790
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Human colon adenocarcinomas from patients with TLR4-D299G were more frequently of an advanced stage (International Union Against Cancer [UICC] ≥III, 70% vs 46%; P = .0142) with metastasis (UICC IV, 42% vs 19%; P = .0065) than those with wild-type TLR4.
|
21920464 |
2011 |
|
rs4986790
|
|
|
0.060 |
GeneticVariation |
BEFREE |
In a prospective cohort study, we examined 62 patients undergoing major surgical cancer therapy for Toll-like receptor 4 (TLR4) gene polymorphisms (Asp299Gly and Thr399Ile) and their influence on cytokine levels pre- and postoperatively, as well as cytokine levels after whole blood lipopolysaccharide (LPS) stimulation.
|
16525349 |
2006 |
|
rs4986791
|
|
|
0.060 |
GeneticVariation |
BEFREE |
In a prospective cohort study, we examined 62 patients undergoing major surgical cancer therapy for Toll-like receptor 4 (TLR4) gene polymorphisms (Asp299Gly and Thr399Ile) and their influence on cytokine levels pre- and postoperatively, as well as cytokine levels after whole blood lipopolysaccharide (LPS) stimulation.
|
16525349 |
2006 |
|
rs11536889
|
|
|
0.020 |
GeneticVariation |
BEFREE |
To obtain an assessment of the effect of TLR4 polymorphisms (rs4986790, rs4986791 and rs11536889) on cancer risk, fifty-five articles (containing 20107 cases and 28244 controls) were recruited for meta-analysis.
|
29246004 |
2017 |
|
rs11536889
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We did not detect any association between rs11536889 and overall cancer risk (P = 0.13).
|
26782430 |
2015 |
|
rs1927911
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our meta-analysis identified that two SNPs (rs4986790 and rs4986791) in TLR4 were associated with increased cancer risk (for rs4986790: OR=1.24, 95% CI=1.01-1.52 in dominant model; OR=1.24, 95% CI=1.02-1.52 in overdominant model; for rs4986791: OR=1.81, 95% CI=1.18-2.77 in allele comparison; OR=1.79, 95% CI=1.15-2.80 in dominant model; OR=1.70, 95% CI=1.09-2.67 in overdominant model) and one SNP (rs1927911) in TLR4 was associated with decreased cancer risk (for rs1927911: OR=0.63, 95% CI=0.41-0.99 in allele comparison; OR=0.57, 95% CI=0.35-0.95 in dominant model; OR=0.67, 95% CI=0.46-0.97 in codominant model).
|
23084080 |
2013 |
|
rs2149356
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To assess the effect of six selected SNPs (rs1927914, rs4986790, rs4986791, rs11536889, rs1927911 and rs2149356) in TLR4 on cancer, we conducted a meta-analysis, up to February 2012, 22 case-control studies were available.
|
23084080 |
2013 |